BioSpace News Archive

Immunome, Inc., a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced that its three-antibody cocktail has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda and Delta AY.1/2 variants, in pre-clinical testing conducted by Immunome on lentiviral-based pseudovirus.

Lexaria Bioscience Corp. is extremely pleased to issue initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH TM -processed cannabidiol for potential application against hypertension.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences.

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), announced it has partnered with Principal Investigator Dr. Matthew Johnson of Johns Hopkins University on a study evaluating the administration of MYCO-001 with a structured smoking cessation treatment program in nicotine dependent individuals.

Abeona Therapeutics Inc. today announced that members of the company’s management will present and conduct one-on-one meetings at the following virtual investor conferences: Citi’s 16th Annual BioPharma Virtual Conference on September 8-10, 2021

Calyxt, Inc. today announced that a presentation given by management at the H.C Wainwright 23rd Annual Global Investment Conference will be available for viewing online on September 13th at 7:00 a.m. ET . The conference will be held in a virtual meeting format.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021.

Baudax Bio, Inc., a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Merck, known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration in China in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction.

Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences in September.